Skip to main content
SpringerLink
Log in

Biologic Therapies

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 1606 Accesses

Abstract

This chapter will review the use of biologic therapies other than infliximab, namely adalimumab, certolizumab pegol (CDP871), CDP571, golimumab, etanercept, onercept, anti-adhesion molecules (natalizumab, vedolizumab, AJM 300, alicaforsen ISIS 2302, anti-interleukin 12/23, briakinumab, ustekinumab, apilimod mesylate), anti-interleukin-2 receptor antibodies (daclizumab, basiliximab) and other miscellaneous biotechnology agents (sargramostim, filgrastim, interleukin 10, fontolizumab, visilizumab, RDP58, abatacept, antagonist to chemokine receptor 9, golimumab) for the treatment of Crohn disease and ulcerative colitis, with an emphasis on use in pediatric patients. Included in the review will be information on the mechanisms of action for the various agents, efficacy, and toxicity. When appropriate, data from clinical trials of these agents in children with dermatologic and rheumatologic disease will be included in order to give the reader the maximum information currently available on the use of these agents in children.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251–8.

    Article  PubMed  CAS  Google Scholar 

  2. Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis. 2006;12:22–8.

    Article  PubMed  Google Scholar 

  3. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288–98.

    Google Scholar 

  4. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62:1168–77.

    Article  PubMed  CAS  Google Scholar 

  5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.

    Article  PubMed  CAS  Google Scholar 

  6. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700–21.

    Article  PubMed  CAS  Google Scholar 

  7. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563–71.

    PubMed  CAS  Google Scholar 

  8. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.

    Article  PubMed  CAS  Google Scholar 

  9. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400–11.

    Article  PubMed  CAS  Google Scholar 

  10. Rau R, Simianer S, van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol. 2004;33:145–53.

    Article  PubMed  CAS  Google Scholar 

  11. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.

    Article  PubMed  CAS  Google Scholar 

  12. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46.

    Article  PubMed  CAS  Google Scholar 

  13. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial. Gastroenterology. 2006;130:323–33.

    Article  PubMed  CAS  Google Scholar 

  14. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–9.

    Article  PubMed  CAS  Google Scholar 

  15. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:56–65.

    Article  Google Scholar 

  16. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.

    PubMed  Google Scholar 

  17. Panaccione R, Hanauer SB, Fedorak R, Rutgeerts P, Sandborn WJ, Pollack P. Concomitant immunosuppressive and adalimumab therapy in Crohn’s disease: 1-year results of the Classic II study. Gastroenterology. 2006;130 Suppl 2:A-479.

    Google Scholar 

  18. Hanauer SB, D’Haens GR, Colombel JF, Sandborn WJ, Kent JD, Pollack PF. Sustained clinical remission in patients with moderate to severe Crohn’s disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. Am J Gastroenterol. 2006;101:S457. Abstract 1173.

    Google Scholar 

  19. Schwartz D, Rutgeerts P, Colombel JF, Sandborn WJ, Hanauer SB, Kent JD, et al. Induction, maintenance, and sustainability of the healing of draining fistulas in patients with Crohn’s disease treated with adalimumab: results of the CHARM study. Am J Gastroenterol. 2006;101:S458–459. Abstract 1177.

    Google Scholar 

  20. Hanauer SB, Kamm MA, Colombel JF, Sandborn WJ, Rutgeerts P, Kent JD, et al. Sustained steroid-free clinical remission in patients with moderate to severe Crohn’s disease treated with adalimumab. Am J Gastroenterol. 2006;101:S460. Abstract 1181.

    Article  Google Scholar 

  21. Prescribing information for Humira (adalimumab). 2011. Abbott Laboratories. North Chicago, IL 60064.

    Google Scholar 

  22. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–7.

    Article  PubMed  CAS  Google Scholar 

  23. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65. e1-3.

    Article  PubMed  CAS  Google Scholar 

  24. Hyams JS, Griffiths AM, Markowitz J, Baldassano R, Faubion WA, Colletti RB, et al. Induction and maintenance adalimumab for moderate to severe Crohn’s disease in children: a randomized double-blind trial. Gastroenterology. 2011;140:S-90.

    Google Scholar 

  25. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2006;54:890.

    Article  Google Scholar 

  26. Sanchez Munoz D, Hoyas Pablos E, Ramirez Martin Del Campo M, Nunez Hospital D, Guerrero Jimenez P. Gestacion a termino en paciente con enfermedad de Crohn en tratamiento con adalimumab. Gastroenterol Hepatol. 2005;28:435.

    Article  PubMed  CAS  Google Scholar 

  27. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis. 2006;12:827–8.

    Article  PubMed  Google Scholar 

  28. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci. 2006;51:2045–7.

    Article  PubMed  Google Scholar 

  29. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–54.

    Article  PubMed  Google Scholar 

  30. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863–9.

    Article  PubMed  CAS  Google Scholar 

  31. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

    Article  PubMed  CAS  Google Scholar 

  32. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65: 889–94.

    Article  PubMed  CAS  Google Scholar 

  33. Nesbitt AM, Henry AJ. High affinity and potency of the pegylated FAB’ fragment CDP870—a direct comparison with other anti-TNF agents. Am J Gastroenterol. 2004;99:S253.

    Google Scholar 

  34. Fossati G, Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol. 2005;100(Supplement):S299.

    Google Scholar 

  35. Fossati G, Nesbitt A. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol. 2005;100 (Supplement):S298–9.

    Google Scholar 

  36. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. for the CCsDSG. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18.

    Article  PubMed  CAS  Google Scholar 

  37. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther. 2004;20:1337–46.

    Article  PubMed  CAS  Google Scholar 

  38. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled Phase III study (PRECiSE 1). Gastroenterology. 2006;130:A-107. Abstract 743.

    Google Scholar 

  39. Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, Bloomfield R, et al. Certolizumab pegol, a humanised anti-TNF pegylated FAb’ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (Precise). Gut. 2005;54:A82. Suppl VII.

    Article  Google Scholar 

  40. Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670–8. e3.

    Article  PubMed  CAS  Google Scholar 

  41. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010;8:696–702. e1.

    Article  PubMed  CAS  Google Scholar 

  42. www.clinicaltrials.gov Accessed April 2012.

    Google Scholar 

  43. Schreiber S, Feagan B, Hanauer SB, Rutgeerts P, McColm JA, Sandborn WJ. Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn’s disease (CD): results from two Phase III studies (PRECiSE program). Gastroenterology. 2006;130:A-479. Abstract T1126.

    Google Scholar 

  44. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology. 2002;41:1133–7.

    Article  PubMed  CAS  Google Scholar 

  45. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet. 1997;349: 521–4.

    Article  PubMed  CAS  Google Scholar 

  46. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330–8.

    Article  PubMed  CAS  Google Scholar 

  47. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomised, double-blind, placebo-controlled trial. Gut. 2004;53:1485–93.

    Article  PubMed  CAS  Google Scholar 

  48. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn’s disease. Aliment Pharmacol Ther. 2005;21:373–84.

    Article  PubMed  CAS  Google Scholar 

  49. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP517, a humanized monoclonal antibody to tumor necrosis factor-a, for steroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:617–28.

    Article  PubMed  CAS  Google Scholar 

  50. Mamula P, Cohen SA, Ferry GD, Kirschner BS, Winter HS, Innes A, et al. Pediatric Inflammatory Bowel Disease C. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn’s disease. Inflamm Bowel Dis. 2004;10: 723–30.

    Article  PubMed  Google Scholar 

  51. van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apopotosis in lamina propria T-lymphocytes from patients with Crohn’s diseease. Gastroenterology. 2003;124:1774–85.

    Article  PubMed  CAS  Google Scholar 

  52. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. [see comment]. N Engl J Med. 2003;349:2014–22.

    Article  PubMed  CAS  Google Scholar 

  53. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–32. discussion 1632.

    Article  PubMed  CAS  Google Scholar 

  54. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.

    Article  PubMed  CAS  Google Scholar 

  55. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.[see comment]. Lancet. 2006;367:29–35.

    Article  PubMed  CAS  Google Scholar 

  56. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]. Lancet. 2000;356:385–90.

    Article  PubMed  CAS  Google Scholar 

  57. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50: 2264–72.

    Article  PubMed  CAS  Google Scholar 

  58. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–86.

    PubMed  CAS  Google Scholar 

  59. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.

    Article  PubMed  CAS  Google Scholar 

  60. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349–56.

    Article  PubMed  CAS  Google Scholar 

  61. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.[see comment]. Arthritis Rheum. 2003;48:1667–75.

    Article  PubMed  CAS  Google Scholar 

  62. Davis Jr JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230–6.

    Article  PubMed  CAS  Google Scholar 

  63. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594–600.

    Article  PubMed  CAS  Google Scholar 

  64. van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, et al. Etanercept Study I. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572–7.

    Article  PubMed  CAS  Google Scholar 

  65. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.[see comment]. N Engl J Med. 2000;342:763–9.

    Article  PubMed  CAS  Google Scholar 

  66. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn’s disease: a randomized, ­double-blind, placebo-controlled trial. Gastroenterology. 2001; 121:1088–94.

    Article  PubMed  CAS  Google Scholar 

  67. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185–92.

    Article  PubMed  CAS  Google Scholar 

  68. Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, et al. Onercept (recombinant human p55 tumor necrosis factor receptor) for moderate-to-severe Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:888–93.

    Article  PubMed  CAS  Google Scholar 

  69. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. International Natalizumab Multiple Sclerosis Trial G. A controlled trial of natalizumab for relapsing multiple sclerosis.[see comment]. N Engl J Med. 2003;348:15–23.

    Article  PubMed  CAS  Google Scholar 

  70. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.[see comment]. N Engl J Med. 2006;354:899–910.

    Article  PubMed  CAS  Google Scholar 

  71. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.[see comment]. N Engl J Med. 2006;354:911–23.

    Article  PubMed  CAS  Google Scholar 

  72. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001;121:268–74.

    Article  PubMed  CAS  Google Scholar 

  73. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348:24–32.

    Article  PubMed  CAS  Google Scholar 

  74. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.

    Article  PubMed  CAS  Google Scholar 

  75. Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Maintenance therapy with natalizumab does not require use of concomitant iImmunosuppressants for sustained efficacy in patients with active Crohn’s disease: results from the ENACT-2 study. Gastroenterology. 2006;130:A-482. Abstract 1137.

    Google Scholar 

  76. Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Natalizumab maintains remission in patients with moderately to severely active Crohn’s disease for up to 2-years: results from an open-label extension study. Gastroenterology. 2006;130:A111. Abstract 768.

    Google Scholar 

  77. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.

    Article  PubMed  CAS  Google Scholar 

  78. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission whil receiving infliximab. Inflammatory Bowel Disease. 2007;13:2–11.

    Article  Google Scholar 

  79. Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16:699–705.

    Article  PubMed  CAS  Google Scholar 

  80. Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185–91.

    Article  PubMed  CAS  Google Scholar 

  81. Prescribing information for Tysabri (natalizumab). 2007.

    Google Scholar 

  82. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.[see comment]. N Engl J Med. 2005;353:369–74.

    Article  PubMed  CAS  Google Scholar 

  83. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.[see comment]. N Engl J Med. 2005;353:375–81.

    Article  PubMed  CAS  Google Scholar 

  84. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease.[see comment]. N Engl J Med. 2005;353:362–8.

    Article  PubMed  Google Scholar 

  85. Yousry TA, Major EO, Rysckewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephaolopathy. N Engl J Med. 2006;354:924–33.

    Article  PubMed  CAS  Google Scholar 

  86. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370–7.

    Article  PubMed  CAS  Google Scholar 

  87. Feagan B, McDonald J, Greenberg G, Wild G, Pare P, Fedorak R, et al. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology. 2000;118:A874.

    Article  Google Scholar 

  88. Feagan BG, Greenberg GR, Wild G, Fedorak R, Pare P, McDonald JWD, et al. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med. 2005;352:2499–507.

    Article  PubMed  CAS  Google Scholar 

  89. Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009;1:CD007571.

    Google Scholar 

  90. Takazoe M, Watanabe M, Kawaguchi T, Matsumoto T, Oshitani N, Hiwatashi N, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease—a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;136:A-181.

    Article  Google Scholar 

  91. Shanahan Jr WR. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert Opin Investig Drugs. 1999;8:1417–29.

    Article  PubMed  CAS  Google Scholar 

  92. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology. 1998;114:1133–42.

    Article  PubMed  CAS  Google Scholar 

  93. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51:30–6.

    Article  PubMed  CAS  Google Scholar 

  94. Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol. 2007;5:215–20.

    Article  PubMed  CAS  Google Scholar 

  95. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology. 2001;120:1339–46.

    Article  PubMed  CAS  Google Scholar 

  96. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646–51.

    Article  PubMed  CAS  Google Scholar 

  97. Van Deventer SJH, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415–25.

    Article  PubMed  CAS  Google Scholar 

  98. Miner PB, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23:1403–13.

    Article  PubMed  CAS  Google Scholar 

  99. Miner Jr PB, Geary RS, Matson J, Chuang E, Xia S, Baker BF, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1427–34.

    Article  PubMed  CAS  Google Scholar 

  100. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19:281–6.

    Article  PubMed  CAS  Google Scholar 

  101. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606–10.

    PubMed  CAS  Google Scholar 

  102. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007;13:26–8.

    Article  PubMed  CAS  Google Scholar 

  103. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.[see comment]. Science. 2006;314:1461–3.

    Article  PubMed  CAS  Google Scholar 

  104. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12:9–15.

    Article  PubMed  Google Scholar 

  105. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351:2069–79.

    Article  PubMed  CAS  Google Scholar 

  106. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.[see comment]. J Invest Dermatol. 2004;123:1037–44.

    Article  PubMed  CAS  Google Scholar 

  107. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177:4917–26.

    PubMed  CAS  Google Scholar 

  108. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–92.

    Article  PubMed  CAS  Google Scholar 

  109. Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. 2006;22:1671–8.

    Article  PubMed  CAS  Google Scholar 

  110. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796–804.

    Article  PubMed  CAS  Google Scholar 

  111. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.

    Article  PubMed  CAS  Google Scholar 

  112. Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn’s disease. Inflammatory Bowel Disease. 2006;12:558–65.

    Article  Google Scholar 

  113. Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease. Inflamm Bowel Dis. 2010;16:1209–18.

    PubMed  Google Scholar 

  114. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003;98:369–76.

    Article  PubMed  Google Scholar 

  115. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, et al. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-ranging trial. Gut. 2006;55: 1568–74.

    Article  PubMed  CAS  Google Scholar 

  116. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18:65–75.

    Article  PubMed  CAS  Google Scholar 

  117. Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435–42.

    Article  PubMed  CAS  Google Scholar 

  118. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Van Assche G, Stempien MJ, et al. A randomized, double-blind placebo-controlled trial of basiliximab with concomitant corticosteroids in steroid-refractory ulcerative colitis. Gastroenterology. 2009; 136:A-65.

    Article  Google Scholar 

  119. Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr. 2002;161 Suppl 1:S88–92.

    PubMed  Google Scholar 

  120. Hoover EG, DuBois JJ, Samples TL, McCullough JS, Chenaille PJ, Montes RG. Treatment of chronic enteritis in glycogen storage disease type IB with granulocyte colony-stimulating factor. J Pediatr Gastroenterol Nutr. 1996;22:346–50.

    Article  PubMed  CAS  Google Scholar 

  121. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn’s disease with recombinant human granulocyte- macrophage colony-stimulating factor. Lancet. 2002;360:1478–80.

    Article  PubMed  Google Scholar 

  122. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn’s Disease Study Group. Sargramostim for active Crohn’s disease. N Engl J Med. 2005;352:2193–201.

    Article  PubMed  CAS  Google Scholar 

  123. Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009;58:1354–62.

    Article  PubMed  CAS  Google Scholar 

  124. Feagan B, Anderson F, Radford-Smith G, Solovyov O, Zurdel-Dillinger S. Efficacy and safety of sargramostim in moderate to severe Crohn’s disease: results of N.O.V.E.L. 4, a phase III multicenter study. Gastroenterology. 2007;132:A-103.

    Google Scholar 

  125. Kelsen JR, Rosh J, Heyman M, Winter HS, Ferry G, Cohen S, et al. Phase I trial of sargramostim in pediatric Crohn’s disease. Inflamm Bowel Dis. 2010;16:1203–8.

    PubMed  Google Scholar 

  126. Mannon PJ, Leon F, Fuss IJ, et al. Increased IL-10 production by peripheral blood memory T cells accompanies Crohn’s disease (CD) remission and clinical response induced by G-CSF treatment. Gastroenterology. 2006;130:W1220.

    Google Scholar 

  127. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn’s disease. Aliment Pharmacol Ther. 2005;21:391–400.

    Article  PubMed  CAS  Google Scholar 

  128. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn’s disease. N Engl J Med. 1999;340:239–40.

    Article  PubMed  CAS  Google Scholar 

  129. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003;38:859–68.

    PubMed  CAS  Google Scholar 

  130. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001;167:4075–82.

    PubMed  CAS  Google Scholar 

  131. Maini R, Paulus HE, Breedveld FC. rHuIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum. 1997;1997:S224.

    Google Scholar 

  132. Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol. 1999;26:2089–93.

    PubMed  CAS  Google Scholar 

  133. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology. 1997;113:383–9.

    Article  PubMed  Google Scholar 

  134. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473–82.

    Article  PubMed  CAS  Google Scholar 

  135. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461–72.

    Article  PubMed  CAS  Google Scholar 

  136. Fedorak R, Nielsen O, Williams N, Malchow H, Forbes A, Stein B, et al. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn’s disease. Gastroenterology. 2001;120:A-127.

    Google Scholar 

  137. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.[see comment]. Gut. 2002;50:191–5.

    Article  PubMed  CAS  Google Scholar 

  138. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut. 2001;49:42–6.

    Article  PubMed  CAS  Google Scholar 

  139. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin- 10. Science. 2000;289:1352–5.

    Article  PubMed  CAS  Google Scholar 

  140. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.[see comment]. Nat Biotechnol. 2003;21:785–9.

    Article  PubMed  CAS  Google Scholar 

  141. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. Eur J Pharm Biopharm. 2005;59:9–15.

    Article  PubMed  CAS  Google Scholar 

  142. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Eur J Pharm Biopharm. 2005;60:349–59.

    Article  PubMed  CAS  Google Scholar 

  143. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754–9.

    Article  PubMed  CAS  Google Scholar 

  144. Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s disease.[see comment]. Gut. 2006;55:1138–44.

    Article  PubMed  CAS  Google Scholar 

  145. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease.[see comment]. Gut. 2006;55:1131–7.

    Article  PubMed  CAS  Google Scholar 

  146. Reinisch W, de Villiers W, Bene L, Simon L, Racz I, Katz S, et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233–42.

    PubMed  Google Scholar 

  147. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007;133:1414–22.

    Article  PubMed  CAS  Google Scholar 

  148. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:620–9.

    PubMed  Google Scholar 

  149. Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010;59:1485–92.

    Article  PubMed  CAS  Google Scholar 

  150. Hommes D, Targan S, Dignass A, Baumgart D, Mayer L, Zang L, et al. Visilizumab therapy in subjects with moderate-to-severe, refractory Crohn’s disease. Gastroenterology. 2007;130:A-157.

    Google Scholar 

  151. Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11:713–9.

    Article  PubMed  Google Scholar 

  152. Preliminary results of Sangstat’s phase 2 studies of RDP58 show peak response of 77% and a 71% remission rate in ulcerative colitis patients. Additional investigation needed to determine efficacy in Crohn’s disease. Internet Press Release 2003.

    Google Scholar 

  153. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470–9.

    Article  PubMed  CAS  Google Scholar 

  154. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–15.

    Article  PubMed  CAS  Google Scholar 

  155. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective ­costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.[see comment][erratum appears in Arthritis Rheum. Oct;52(10):3321]. Arthritis Rheum. 2005;52:2263–71.

    Article  PubMed  CAS  Google Scholar 

  156. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.[erratum appears in N Engl J Med. 2005 Nov 24;353(21):2311]. N Engl J Med. 2005;353:1114–23.

    Article  PubMed  CAS  Google Scholar 

  157. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.[see comment][summary for patients in Ann Intern Med. 2006 Jun 20;144(12):I18; PMID: 16785473]. Ann Intern Med. 2006;144:865–76.

    PubMed  CAS  Google Scholar 

  158. Hanauer SB, Sandborn WJ, Sands BE, Rutgeerts PJ, Panaccione R, Bressler B, et al. A randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn’s disease (CD). Gastroenterology. 2007;107:S-86.

    Google Scholar 

  159. http://ctr.bms.com/pdf//IM101-108%20ST.pdf.

    Google Scholar 

  160. Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut. 2006;55:1059–60.

    Article  PubMed  CAS  Google Scholar 

  161. Keshav S, Ungashe S, Zheng W, Bekker P, Wright K, Schall T. Ccx282-B, an orally active inhibitor of Chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn’s disease. Gastroenterology. 2007;132:A-157.

    Google Scholar 

  162. Keshav S, Johnson D, Bekker P, Schall TJ. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate to severe Crohn’s disease. Gastroenterology. 2009;136:A-65.

    Article  Google Scholar 

  163. Keshav S, Johnson D, Schall T, Bekker P. Chemokine receptor antagonist CCX282-B (Traficet-En™) maintained remission of Crohn’s disease in PROTECT-1 study. Gastroenterology. 2010; 138:S-86.

    Article  Google Scholar 

  164. Shealy D, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2:428–439.

    Article  Google Scholar 

  165. Sandbor WJ, Feagan BG, Marano CW, Strauss R, Johanns J, Zhang H, et al. A Phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative Colitis: PURSUIT SC. Gastroenterology. 142(5):S1–161.

    Article  Google Scholar 

  166. Ben-Bassat O, Iacono A, Irwin SP, Silverberg MS, Greenberg GR. Golimumab for treatment of moderate to severe anti-TNF refaractory Crohn’s disease: open label experience. Gastroenterology. 142(5):S1–804.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA

    Wojciech Blonski MD, PhD

  2. Department of Gastroenterology, Medical University, Wroclaw, Wroclaw, Poland

    Wojciech Blonski MD, PhD

  3. Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Faten Aberra MD

  4. Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3400 Spruce Street, 9 Penn Tower, Philadelphia, PA, 19104-4283, USA

    Gary R. Lichtenstein MD

Authors
  1. Wojciech Blonski MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faten Aberra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Lichtenstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary R. Lichtenstein MD .

Editor information

Editors and Affiliations

  1. Perelman School of Medicine, The Children’s Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Petar Mamula

  2. School of Medicine--Greenville, Pediatric Gastroenterology & Nutrition, University of South Carolina, 200 Patewood Drive, Suite A-140, Greenville, 29615, South Carolina, USA

    Jonathan E. Markowitz

  3. Perelman School of Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Robert N. Baldassano

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Blonski, W., Aberra, F., Lichtenstein, G.R. (2013). Biologic Therapies. In: Mamula, P., Markowitz, J., Baldassano, R. (eds) Pediatric Inflammatory Bowel Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5061-0_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5061-0_34

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5060-3

  • Online ISBN: 978-1-4614-5061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation